Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Genelabs Technologies logo — company profile

Genelabs Technologies

Founded 1983 24 employees Venture round Total: $17.30M Biopharma, Biotechnology +2

General Information

Company Name Genelabs Technologies
Founded Year 1983
Founders / Decision Makers
Team member
Employees 24
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Genelabs Technologies. To contact Genelabs Technologies, visit genelabs.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Genelabs Technologies compare?

A PDF of Genelabs Technologies and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Genelabs Technologies soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Genelabs Technologies

Genelabs Technologies is a biopharmaceutical company founded in 1983, focusing on the discovery and development of novel compounds for infectious diseases. The company has a late-stage drug candidate for Hepatitis E that is partnered with GlaxoSmithKline. Additionally, it is advancing multiple partnered and proprietary compounds designed to selectively inhibit the replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009, Genelabs was acquired by GlaxoSmithKline. The last recorded investment for the company was a $9.00M Venture Round investment on 30 June 2007. Despite the lack of a headquarters mentioned, Genelabs Technologies operates within the Biopharma, Biotechnology, Health Care, Health, and Wellness industries.

Business keywords: biopharmaceutical company, infectious diseases, Hepatitis E, Hepatitis C virus, drug development, antiviral compounds, GlaxoSmithKline, pharmaceutical partnerships, clinical trials, vaccine development, systemic lupus erythematosus, collaborative research, National Health Research Institutes, Genovate Biotechnology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $9.00M -
30 Jun 2007
Venture Round $8.30M 5
RA Capital Management Merlin Biomed Fort Mason Capital
RA Capital Management, Merlin Biomed +3
27 Jun 2006

Genelabs Technologies Alternatives & Competitors

View All Alternatives
Genelabs Technologies vs
Idenix Pharmaceuticals
Idenix Pharmaceuticals

Pioneering advancements in antiviral therapies, focused on combating hepatitis and HIV, with a stron...

Post-IPO Equity
Biotechnology, Health Care
Genelabs Technologies vs
VBI Vaccines Inc.
VBI Vaccines Inc. United States

Driven by Immunology in the Pursuit of Powerful Prevention and Treatment of Disease

Post-IPO Equity
57 employees
Biotechnology, Health Care
Genelabs Technologies vs
Soligenix, Inc.
Soligenix, Inc. United States

We are a late-stage biopharmaceutical company focused on developing & commercializing products to tr...

Post-IPO Equity
27 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Genelabs Technologies

Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to se...
Genelabs Technologies was founded in 1983.
Genelabs Technologies operates in Biopharma, Biotechnology, Health Care and Health and Wellness. Its work centres on biopharmaceutical company, infectious diseases, Hepatitis E and Hepatitis C virus.
Genelabs Technologies has approximately 24 employees.
Genelabs Technologies has completed 2 funding rounds, raising a total of $17.30M. The latest funding stage is Venture round.
Top alternatives and competitors to Genelabs Technologies include Idenix Pharmaceuticals, VBI Vaccines Inc., Soligenix, Inc., Osivax, Santaris Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Genelabs Technologies and Idenix Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Genelabs Technologies, https://bouncewatch.com/company/genelabs-technologies, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes